Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer.

ABSTRACT:

Purpose

Androgen deprivation therapy (ADT) remains the backbone of prostate cancer treatment. Beyond the suppression of testosterone and tumor cell growth, emerging evidence suggests that ADT also modulates the immune tumor microenvironment. However, a more precise understanding of the timing and intricacies of these immunologic shifts is needed.

Experimental design

In this study, we analyzed 49 primary prostate cancers, comparing those surgically removed either without treatment or following treatment with degarelix at 4, 7, and 14 days before surgery. Utilizing next-generation DNA and RNA sequencing and multiplexed immunofluorescence, we examined alterations in immune phenotypes in the presence or absence of ADT.

Results

Our findings reveal that ADT rapidly transfor

SUBMITTER: Dallos MC 

PROVIDER: S-EPMC11905119 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature